Your browser doesn't support javascript.
loading
What Represents Treatment Efficacy in Long-term Studies of Gout Flare Prevention? An Interview Study of People With Gout.
Holyer, Jeremy; Garcia-Guillen, Andrea; Taylor, William J; Gaffo, Angelo L; Gott, Merryn; Slark, Julia; Horne, Anne; Su, Isabel; Dalbeth, Nicola; Stewart, Sarah.
Afiliación
  • Holyer J; J. Holyer, medical student, A. Garcia-Guillen, MD, M. Gott, PhD, J. Slark, PhD, A. Horne, MBChB, I. Su, BSc, N. Dalbeth, MBChB, MD, FRACP, S. Stewart, PhD, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • Garcia-Guillen A; J. Holyer, medical student, A. Garcia-Guillen, MD, M. Gott, PhD, J. Slark, PhD, A. Horne, MBChB, I. Su, BSc, N. Dalbeth, MBChB, MD, FRACP, S. Stewart, PhD, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • Taylor WJ; W.J. Taylor, MBChB, PhD, FRACP, FAFRM, Department of Medicine, University of Otago, Wellington, New Zealand.
  • Gaffo AL; A.L. Gaffo, MD, MSPH, FACP, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Gott M; J. Holyer, medical student, A. Garcia-Guillen, MD, M. Gott, PhD, J. Slark, PhD, A. Horne, MBChB, I. Su, BSc, N. Dalbeth, MBChB, MD, FRACP, S. Stewart, PhD, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • Slark J; J. Holyer, medical student, A. Garcia-Guillen, MD, M. Gott, PhD, J. Slark, PhD, A. Horne, MBChB, I. Su, BSc, N. Dalbeth, MBChB, MD, FRACP, S. Stewart, PhD, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • Horne A; J. Holyer, medical student, A. Garcia-Guillen, MD, M. Gott, PhD, J. Slark, PhD, A. Horne, MBChB, I. Su, BSc, N. Dalbeth, MBChB, MD, FRACP, S. Stewart, PhD, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • Su I; J. Holyer, medical student, A. Garcia-Guillen, MD, M. Gott, PhD, J. Slark, PhD, A. Horne, MBChB, I. Su, BSc, N. Dalbeth, MBChB, MD, FRACP, S. Stewart, PhD, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • Dalbeth N; J. Holyer, medical student, A. Garcia-Guillen, MD, M. Gott, PhD, J. Slark, PhD, A. Horne, MBChB, I. Su, BSc, N. Dalbeth, MBChB, MD, FRACP, S. Stewart, PhD, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
  • Stewart S; J. Holyer, medical student, A. Garcia-Guillen, MD, M. Gott, PhD, J. Slark, PhD, A. Horne, MBChB, I. Su, BSc, N. Dalbeth, MBChB, MD, FRACP, S. Stewart, PhD, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand; sarah.stewart@auckland.ac.nz.
J Rheumatol ; 48(12): 1871-1875, 2021 12.
Article en En | MEDLINE | ID: mdl-34470799
OBJECTIVE: The patient experience of gout flares is multidimensional, with several contributing factors including pain intensity, duration, and frequency. There is currently no consistent method for reporting gout flare burden in long-term studies. This study aimed to determine which factors contribute to patient perceptions of treatment efficacy in long-term studies of gout flare prevention. METHODS: This study involved face-to-face interviews with people with gout using visual representations of gout flare patterns. Participants were shown different flare scenarios over a hypothetical 6-month treatment period that portrayed varying flare frequency, pain intensity, and flare duration. The participants were asked to indicate and discuss which scenario they believed was most indicative of successful treatment over time. Quantitative data relating to the proportion of participants selecting each scenario were reported using descriptive statistics. A qualitative descriptive approach was used to code and categorize the data from the interview transcripts. RESULTS: Twenty-two people with gout participated in the semistructured interviews. All 3 factors of pain intensity, flare duration, and flare frequency influenced participants' perception of treatment efficacy. However, a shorter flare duration was the most common indicator of successful treatment, with half of participants (n = 11, 50%) selecting the scenario with a shorter flare duration over those with less painful flares. CONCLUSION: Flare duration, flare frequency, and pain severity are all taken into account by patients with gout when considering treatment efficacy over time. Long-term studies of gout should ideally capture all these factors to better represent patients' experience of treatment success.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Gota Tipo de estudio: Qualitative_research Límite: Humans Idioma: En Revista: J Rheumatol Año: 2021 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Gota Tipo de estudio: Qualitative_research Límite: Humans Idioma: En Revista: J Rheumatol Año: 2021 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Canadá